Abstract-To investigate the cellular mechanisms for altered Ca 2ϩ homeostasis and contractility in cardiac hypertrophy, we measured whole-cell L-type Ca 2ϩ currents (I Ca,L ), whole-cell Ca 2ϩ transients ([Ca 2ϩ ] i ), and Ca 2ϩ sparks in ventricular cells from 6-month-old spontaneously hypertensive rats (SHRs) and from age-and sex-matched Wistar-Kyoto and Sprague-Dawley control rats. By echocardiography, SHR hearts had cardiac hypertrophy and enhanced contractility (increased fractional shortening) and no signs of heart failure. C ardiac hypertrophy is associated with marked changes in myocardial contractility. Peak active tension increases, 1-4 and the rates of both contraction and relaxation are slowed. 3, [5] [6] [7] [8] These contractile abnormalities are associated with alterations in the whole-cell calcium transient ([Ca 2ϩ ] i ). In the hypertrophied myocardium, the amplitude of [Ca 2ϩ ] i increases, 9 whereas in failing myocardium, the amplitude of [Ca 2ϩ ] i decreases. 10 -13 In most animal models of hypertrophy 8, 10, 11, [13] [14] [15] and in failing human hearts, 12,16 the duration of the whole-cell [Ca 2ϩ ] i is also prolonged. However, the precise cellular mechanisms that are responsible for changes in contractility and alterations in [Ca 2ϩ ] i are largely unknown. Identification of the cellular mechanisms that underlie altered excitation-contraction coupling in cardiac hypertrophy and heart failure is complicated by several issues, including differences in experimental animal models and disease progression. In addition, it has only recently proved possible using confocal microscopy to measure local nonpropagating elevations of Ca 2ϩ (Ca 2ϩ sparks) at the level of individual sarcomeres. [17] [18] [19] [20] [21] [22] The ability to measure Ca 2ϩ sparks provides an opportunity to evaluate directly the role of sarcoplasmic reticulum (SR) Ca 2ϩ release in muscle cells from animal models associated with cardiac hypertrophy.
Abstract-To investigate the cellular mechanisms for altered Ca 2ϩ homeostasis and contractility in cardiac hypertrophy, we measured whole-cell L-type Ca 2ϩ currents (I Ca,L ), whole-cell Ca 2ϩ transients ([Ca 2ϩ ] i ), and Ca 2ϩ sparks in ventricular cells from 6-month-old spontaneously hypertensive rats (SHRs) and from age-and sex-matched Wistar-Kyoto and Sprague-Dawley control rats. By echocardiography, SHR hearts had cardiac hypertrophy and enhanced contractility (increased fractional shortening) and no signs of heart failure. SHR cells had a voltage-dependent increase in peak [ C ardiac hypertrophy is associated with marked changes in myocardial contractility. Peak active tension increases, [1] [2] [3] [4] and the rates of both contraction and relaxation are slowed. 3, [5] [6] [7] [8] These contractile abnormalities are associated with alterations in the whole-cell calcium transient ([Ca 2ϩ ] i ). In the hypertrophied myocardium, the amplitude of [Ca 2ϩ ] i increases, 9 whereas in failing myocardium, the amplitude of [Ca 2ϩ ] i decreases. 10 -13 In most animal models of hypertrophy 8, 10, 11, [13] [14] [15] and in failing human hearts, 12, 16 the duration of the whole-cell [Ca 2ϩ ] i is also prolonged. However, the precise cellular mechanisms that are responsible for changes in contractility and alterations in [Ca 2ϩ ] i are largely unknown. Identification of the cellular mechanisms that underlie altered excitation-contraction coupling in cardiac hypertrophy and heart failure is complicated by several issues, including differences in experimental animal models and disease progression. In addition, it has only recently proved possible using confocal microscopy to measure local nonpropagating elevations of Ca 2ϩ (Ca 2ϩ sparks) at the level of individual sarcomeres. [17] [18] [19] [20] [21] [22] The ability to measure Ca 2ϩ sparks provides an opportunity to evaluate directly the role of sarcoplasmic reticulum (SR) Ca 2ϩ release in muscle cells from animal models associated with cardiac hypertrophy.
In this study, we used laser scanning confocal microscopy and 
Materials and Methods

Animals
Studies were performed on 6-month-old SHRs and age-and sexmatched Wistar-Kyoto and Sprague-Dawley control rats. There were no differences between Wistar-Kyoto and Sprague-Dawley in each of the experiments, and both groups were combined and denoted as control animals. Animals were obtained at 6 to 8 weeks of age and weighed between 180 and 280 g. The heart rates, blood pressure (BP), and respiratory rates of all animals were monitored at monthly intervals. BP was measured using the tail-cuff method. 23 All measurements were obtained while the animal was resting comfortably and were repeated 3 times at each determination. The clinical and echocardiographic characteristics, heart weight (wet)/body weight ratios, and cell capacitance of 6-month-old SHRs and control rats are shown in the Table. At the time of study, all SHRs were hypertensive with a mean systolic BP of 182Ϯ21 mm Hg (nϭ78; PϽ0.05 versus controls), and no animal exhibited any clinical signs of heart failure such as weight loss, tachypnea, resting tachycardia, or pleural and/or pericardial effusions.
In addition, a separate population of SHRs and controls was treated continuously with an angiotensin-converting enzyme inhibitor (lisinopril, 25 mg/(kg body weight ⅐ day) in their drinking water from the time of arrival. Clinical parameters were obtained as with untreated rats, and echocardiographic studies were performed at 18 months of age.
All rats used in the present study were maintained in accordance with the guidelines of the Institutional Animal Care and 
Echocardiographic Studies
Transthoracic echocardiographic studies were performed in rats using standard techniques. 24, 25 Briefly, rats were lightly anesthetized with sodium pentobarbital (10 to 15 mg/kg injected IP). Using a commercially available echocardiographic machine (HewlettPackard Sonos 2000) equipped with a 7.5-MHz transducer, a 2-dimensional short-axis view of the left ventricle (LV) was obtained at the level of the papillary muscles. M-mode tracings were recorded through the anterior and posterior LV walls. The internal dimensions of the LV cavity and the anterior and posterior wall thickness (end systole and end diastole) were measured using a modification of the leading-edge method from the American Society of Echocardiography from 3 consecutive cardiac cycles on the M-mode tracings. The analysis was performed offline (commercial software, HewlettPackard) by 2 echocardiographers (M.C. and J.M.B.), who were blinded to the strain of rat and prior results. The percentage shortening of the endocardium was calculated as (LVDD-LVSD)/ LVDDϫ100, where LVDDϭLV internal diastolic dimension and LVDSϭLV internal systolic dimension.
Pathology and Histology Studies
Animals were deeply anesthetized with sodium pentobarbital (170 mg/kg injected IP), and hearts were removed via midline thoracotomy. The heart was mounted on a Langendorff apparatus and perfused retrograde at 37°C with a physiological salt-containing solution (PSS, see below) containing 1 mmol/L CaCl 2 for 5 minutes, followed by Ca 2ϩ -free PSS for 5 minutes to arrest the heart in diastole. The heart was then perfused with 25 mL of fixative solution consisting of 2.5% glutaraldehyde in 0.1 mmol/L sodium cacodylate buffer (pH 7.3). Cross sections of the heart were obtained at the level of the papillary muscles, and sample pieces of the LV were obtained from the anterior wall and papillary muscles. All samples were stored in fixative at room temperature (21°C to 23°C) for 48 hours and then transferred to cold (4°C) 0.2 mmol/L sodium cacodylate buffer. Some samples were embedded in paraffin, sectioned, and evaluated by standard histological techniques. Samples selected for electron microscopy were postfixed for 1 hour in 1% OsO 4 in 0.1 mmol/L sodium cacodylate buffer (4°C), stained en bloc with 2% uranyl acetate, dehydrated in ethanol, and embedded in Epon. Thin sections were then stained with uranyl acetate and lead citrate and examined in a Phillips EM 201 transmission electron microscope.
For morphometric analysis of cell size, paraffin sections of papillary muscles cut in cross section were examined with a ϫ40-objective lens in a Nikon Microphot microscope equipped with a Hitachi charge-coupled device camera connected to a Sony color video monitor. Morphometric analysis was performed with a commercially available software package (BioQuant, OS2 version 2.5; R&M Biometrics). 26, 27 Briefly, manual tracings of the perimeters of cardiac muscle cells were made from all cells visualized on a field (500ϫ500 m) projected on a video monitor. The area within the perimeter tracings was calculated using the BioQuant software. A total of 160 control and 156 SHR cells were measured from multiple sections taken from 3 control rats and 3 SHRs. influx via L-type Ca 2ϩ channels. The external solution was composed of the following (in mmol/L): NaCl 140, dextrose 10, HEPES 10, CsCl 10, MgCl 2 1, and CaCl 2 1, pH adjusted to 7.3 to 7.4 with NaOH at 25°C. The electrode-filling solution used for whole-cell recording and loading with the fluorescent indicator, Indo 1 (Molecular Probes), was composed of the following (in mmol/L): cesium glutamate 130, HEPES 10, MgCl 2 0.33, Mg 2 -ATP 4, and Indo 1 0.05, pH adjusted to 7.1 to 7.2 with CsOH. The filled micropipette electrodes had resistances of 1.5 to 4.0 M⍀. The holding potential was -50 mV. All experiments were performed at room temperature (21°C to 23°C). Cell capacitance and whole-cell currents were recorded using standard methods. Current was filtered at 5 kHz and digitized at 2 kHz with 12-bit resolution. [Ca 2ϩ ] i was calculated from the Indo 1 fluorescence through the use of "calibration parameters" obtained in situ 28 and was corrected for the kinetics of Indo 1. 29 In selected experiments, unloaded cell shortening was measured simultaneously with I Ca,L and [Ca 2ϩ ] i , using a custom-made edgedetection system. Because high magnification was required for the measurement of [Ca 2ϩ ] i , movement of only a single edge of the cell was monitored. The data from each experiment were normalized to the shortening measured at maximal depolarization to allow for comparison.
Whole
Local SR Ca
2؉ Release: Ca 2؉ Sparks
Cells were loaded with the membrane-permeant form of the Ca 2ϩ indicator, Fluo 3 (Molecular Probes), by incubating the cells for 30 minutes at 21°C to 23°C in PSS containing Fluo 3-AM (10 mmol/L) and pleuronic acid (0.05% wt/vol). Nifedipine (10 mol/L) was added to the external solution to reduce the probability but not the amplitude of single L-type Ca 2ϩ channel currents. Cells were electrically field stimulated with a 50-to 100-mA pulse of 5 ms duration. A series of prepulses [3] [4] [5] was given to ensure a constant amount of use-dependent block by nifedipine. All experiments were performed at room temperature (21°C to 23°C).
Detection and Analysis of Ca 2؉ Sparks
Ca 2ϩ sparks were detected as Fluo 3 fluorescence with confocal microscopy 18, 19 and analyzed with a modification of the Ca 2ϩ spark detection algorithm described previously. 19, 30 Briefly, areas of the line-scan image without elevations in [Ca 2ϩ ] i were selected to represent the background Fluo 3 fluorescence. These areas were then subtracted from the line-scan image. Next, all increases in fluorescence that could be visually identified were chosen for analysis. The spatial location of the peak of the Ca 2ϩ spark was defined, and a portion (30ϫ50 pixels) of the background-subtracted image centered around the Ca 2ϩ spark was extracted and smoothed (recursive boxcar average filter with a width of 3 pixels). The first 3 line scans of this area were averaged to determine the resting fluorescence. The peak amplitude of the Ca 2ϩ spark was determined as the difference between the maximal fluorescence of the Ca 2ϩ spark and the resting fluorescence before the peak of the Ca 2ϩ spark. A threshold level was set at half the difference between the peak amplitude and the resting level. The rate of onset of a Ca 2ϩ spark was defined as the time required for the fluorescence signal to increase from threshold to peak amplitude. The fall time of a Ca 2ϩ spark was defined as the time required for the fluorescence to decrease from peak amplitude to below threshold. The following criteria were used to identify a rise in fluorescence as a Ca 2ϩ spark. (1) The peak amplitude had to remain above threshold for at least 2 consecutive line scans (4 ms).
(2) The fluorescence signal had to fall below threshold within the area analyzed. (3) The area analyzed contained only 1 peak of [Ca 2ϩ ] i elevation. [Ca 2ϩ ] i was calculated from the Fluo 3 fluorescence, with a self-ratio method using an equation and calibration parameters given previously. 17 
Assessment of SR Ca 2؉ Load
The Ca 2ϩ content of the SR was measured using the whole-cell variation of the patch-clamp technique coupled with Indo 1 (Molecular Probes) fluorescence. 31 Briefly, eight 200-ms voltage-clamp steps to 0 mV were applied before data collection to achieve steady-state SR Ca 2ϩ loading. After the prepulses, caffeine (20 mmol/L) was rapidly applied to the cell, eliciting both a [Ca 2ϩ ] i and an inward current that represents the activation of Na ϩ /Ca 2ϩ exchange by the Ca 2ϩ released from the SR. SR load was assessed by both the amplitude of the evoked Ca 2ϩ transient and the integral of the elicited current. The current was integrated offline using Origin (Microcal Software, Inc). All data were normalized to cell capacitance.
Biochemical Methods
Control and SHR hearts were obtained and arrested in diastole as described above. The hearts were then immediately placed in cold (0°C) Ca 2ϩ -PSS and stored at -70°C until analyzed. LV samples (Ϸ110 mg) were homogenized in 2 mL of 0.25 mol/L sucrose and 10 mmol/L histidine (pH 7.2), and [
3 H]ryanodine binding assays were conducted at saturating ryanodine concentration (15 nmol/L). 32 Briefly, a sample of crude homogenate protein (0.38 mg) was incubated for 1 hour at 37°C in 200 L of binding solution, which contained the following: 20 mmol/L MOPS, 1 mmol/L CaCl 2 , 600 mmol/L NaCl, and 15 nmol/L [ 3 H]ryanodine (pH 7.1) with and without 10 mol nonradioactive ryanodine for determination of nonspecific binding. After incubation, 2 mL of iced buffer containing the above solution was added to the mixture, and the samples were filtered through glass fiber type C filters using a cell harvester. The filters were rinsed twice with cold buffer, placed in glass scintillation vials with 7 mL of Altima Gold scintillation fluid, and counted. All experiments were performed in triplicate.
Quantitative immunoblotting of the SR Ca 2ϩ -ATPase, phospholamban, the ryanodine receptor, junctin, triadin, and calsequestrin were performed. 33 The antibodies used were the following: for Ca 2ϩ -ATPase, monoclonal antibody 2A7-A1 32 ; for phospholamban, monoclonal antibody 2D12 33 ; for ryanodine receptor antibody, monoclonal antibody 1E9 34 ; for junctin, affinity-purified antibodies to residues 6 to 20 of canine junctin 32 ; for triadin, affinity-purified antibodies to residues 146 to 159 of mouse triadin 35 ; and for calsequestrin, affinity-purified antibodies to cardiac calsequestrin. 33 125 I-protein A binding bands were quantified with the use of a GS-250 molecular imager (Bio-Rad). 32 All experiments were done in triplicate.
Statistical Analysis
Results are expressed as meanϮSD. Significance was determined using Student t test, with a value of PϽ0.05 considered to be statistically significant.
Results
Characteristics of Cardiac Hypertrophy in SHRs
At 6 months of age, SHRs have systemic hypertension and cardiac hypertrophy without any clinical signs of heart failure, including tachycardia, tachypnea, or edema. As shown in the To evaluate the possibility that the development of cardiac hypertrophy in SHRs was independent of the sustained increases in afterload from systemic hypertension, a cohort of SHRs (and controls) was studied after 18 months of treatment with an angiotensin-converting enzyme inhibitor (lisinopril) at a dose sufficient to restore the BP of SHRs to the levels of untreated controls. As shown in the Table, determinations of the posterior LV wall thickness and fractional shortening in treated SHRs were nearly identical to those in both the treated and 6-month-old controls. The end-diastolic diameters in treated SHRs were similar to those of treated controls, although they were both less than those of the 6-month-old controls, possibly because of treatment with the antihypertensive medication.
The in vivo findings of cardiac hypertrophy in 6-month-old SHRs were also confirmed by a significant increase in the heart weight (LV, wet)/body weight ratio (5.1Ϯ0. 8 Consistent with these findings, Figure 2 shows the pathological and histological changes indicative of cardiac hypertrophy. Cross sections (Figure 2A ) taken from representative hearts at the level of the papillary muscles show slight concentric thickening of the walls of the LV in SHR hearts. From images of transmitted light microscopy ( Figure 2D [SHRs] and Figure 2C . These sections do not show any histological characteristics frequently seen in heart failure, including increased fibrosis and destruction of the myofibrillar structure with misalignment of the myofibrils. The images from transmission electron microscopy also do not show any alterations in sarcomere structure consistent with heart failure, including misalignment of the contractile bands. 36 Therefore, 6-month-old SHRs have hypertension and cardiac hypertrophy that is remarkably similar to hypertensive heart disease in humans. Figure 3B, nϭ24) . When normalized to cell size (as determined from cell capacitance), the peak amplitude of I Ca,L in SHRs is nearly identical to that of controls (peak I Ca,L at 0 mV, 5 
Ca
2؉ Sparks
Since [Ca 2ϩ ] i is determined by multiple cellular processes, of which SR Ca 2ϩ release is just 1, we exploited the enhanced spatial resolution of confocal microscopy to quantify directly the release of Ca 2ϩ from the SR, visualized as Ca 2ϩ sparks. Using this approach, 396 Ca 2ϩ sparks were measured in 13 rat ventricular cells obtained from 5 control rats ( Figure 4A ). Both spontaneous and evoked Ca 2ϩ sparks were included in the analysis, because previous studies have shown that spontaneous Ca 2ϩ sparks are indistinguishable from Ca 2ϩ sparks evoked by electrical stimulation on the basis of similar kinetic characteristics. 18, 19, 22 In control cells, [Ca 2ϩ ] i rises rapidly with an overall mean Ca 2ϩ spark amplitude of 109Ϯ64 nmol/L. However, the distribution of Ca 2ϩ spark amplitudes suggests at least 2 distinct populations ( Figure 4A ). Whereas the majority (87%) of Ca 2ϩ sparks had a mean amplitude of 88Ϯ67 nmol/L, a smaller number (13%) of Ca 2ϩ sparks had significantly larger amplitudes ("big sparks") with a mean elevation in [Ca 2ϩ ] i of 198Ϯ68 nmol/L. Additional distributions could not be reliably detected because of the small number of observed Ca 2ϩ sparks of larger amplitudes.
The temporal and spatial size (area) of Ca 2ϩ sparks varied greatly, and there was no correlation between the amplitude of a Ca 2ϩ spark and its area, rise time, or fall time (r 2 ϭϪ0.05, 0.06, and -0.22, respectively). There was a weakly positive correlation (r 2 ϭ0.52) between the area of the Ca 2ϩ spark and its fall time. If the variation in Ca 2ϩ spark amplitude were due to out-of-focus events, then there should be a negative correlation between Ca 2ϩ spark amplitude and duration. Thus, these results support the notion that the total variation in Ca 2ϩ spark amplitude is not due to the detection of out-of-focus events. 30, 37 Five hundred sixty-two Ca 2ϩ sparks were observed in 17 ventricular cells obtained from 6 SHRs ( Figure 4B) Figure 4A ), SHR Ca 2ϩ spark amplitudes were not normally distributed and were fit better with 2 overlapping distributions. As shown in Figure 4B , these 2 distributions were nearly identical in amplitude to those identified in control cells and included a population with a mean amplitude of 105Ϯ74 nmol/L and a second population with a mean amplitude of 197Ϯ103 nmol/L. In contrast to control Ca 2ϩ sparks, the first distribution comprised only 57% of the population of SHR Ca 2ϩ sparks, while the second distribution contained the remaining 43% of SHR Ca 2ϩ sparks (big sparks). Therefore, the overall increase in Ca 2ϩ spark amplitude in SHR cells appears attributable to a redistribution of the Ca 2ϩ sparks to the larger amplitude population.
Finally, there was no correlation between the amplitude of SHR Ca 2ϩ sparks and the area of spread, rise time, or fall time (r 2 ϭ0.02, 0.01, and 0.003, respectively). In SHR cells, there was also a weak positive correlation between the area encompassed by the Ca 2ϩ spark and its fall time (r 2 ϭ0.47). Consistent with control Ca 2ϩ sparks, the variation in SHR Ca 2ϩ spark amplitude is unlikely to be due to detection of out-of-focus events. 
SR Ca 2؉ Load
The increase in SHR Ca 2ϩ spark amplitude could be due to an increase in the amount of Ca 2ϩ accumulated in the SR. 38 To evaluate this possibility, the SR Ca 2ϩ load under these experimental conditions was determined by measuring both the amplitude of the [Ca 2ϩ ] i and the inward current in response to the rapid application of caffeine to the cell ( Figure   5 ). As shown in Figure 5 , the caffeine-induced [Ca 2ϩ ] i had a peak of 1200Ϯ200 nmol/L, and the total inward charge was available regarding the amount of SR in control and SHRs at this age.
Density of Ryanodine Receptors
To evaluate the possibility that increased SR Ca 2ϩ release in SHRs (both [Ca 2ϩ ] i and Ca 2ϩ sparks) was due to an increase in the numbers of SR Ca 2ϩ release channels (ryanodine receptors), we measured ryanodine-receptor density in hearts from 3 SHRs and 3 control animals. Figure 6 ). Therefore, the increase in SR Ca 2ϩ release observed in SHR cells appears to reflect changes in the efficacy of the trigger signal to elicit SR Ca 2ϩ release.
Discussion
The major finding of this study is that hypertrophic myocytes from SHRs have an increase in the amplitude of [Ca 2ϩ ] i and in the mean amplitude of Ca 2ϩ sparks. This increase in SR Ca 2ϩ release occurs without observable changes in the Ca 2ϩ trigger for SR Ca 2ϩ release (I Ca,L ) or SR Ca 2ϩ content. In addition, there was no alteration in the density of several SR Ca 2ϩ -handling proteins, including those of the free SR and the junctional SR. Thus, these data suggest that the increased (or at least the preservation of) contractility observed with cardiac hypertrophy in SHRs most likely involves an alteration of the coupling of Ca 2ϩ entry through L-type Ca 2ϩ channels and the release of Ca 2ϩ from the SR. In addition, SHR myocytes exhibited a marked prolongation of the relaxation phase of unloaded contractions. However, the time course of [Ca 2ϩ ] i in SHRs was identical to those from control cells, and no alterations in the expression of the Ca 2ϩ -ATPase were found. Collectively, these results indicate that a change either in the Ca 2ϩ affinity of the contractile proteins or in the ultrastructural proteins that maintain cell shape may be responsible, in part, for the diastolic dysfunction observed with hypertensive heart disease.
The observation of normal I Ca,L in hypertrophied SHR cells is in good agreement with data from several animal models of cardiac hypertrophy. I Ca,L density is unaltered in ventricular cells from SHRs, 39, 40 rats with aortic banding, 41 cats with pulmonary artery banding, 42 cardiomyopathic hamsters, 43 and human ventricular cells from failing hearts. 12, 44 This finding is not universal, however, and appears to be both model and experiment dependent. I Ca,L increases in guinea pigs with aortic banding, 45 in rats with renal artery banding, 46 and in 1 report on SHRs. 47 In addition, I Ca,L has been shown to decrease in ventricular cells from cats with aortic banding 48 and ferrets with pulmonary artery banding. 49 Thus, it appears that the I Ca,L is unchanged in most models of hypertension and heart failure.
The relationship between hypertrophy and [Ca 2ϩ ] i amplitude also appears model dependent. In contrast to our findings in cardiac hypertrophy, the vast majority of studies of heart failure show both a decrease in the peak amplitude and a prolongation in the duration of the [Ca 2ϩ ] i . A decrease in the peak [Ca 2ϩ ] i has been observed in myocytes from aorticbanded rats that worsened as heart failure developed, 50 aortic-banded cats, 11 rats with renovascular hypertension, 10 dogs with pacing-induced cardiomyopathies, 14 Dahl saltsensitive rats, 13 a derivative population of SHRs that develop accelerated heart failure (spontaneously hypertensive-heart failure [SH-HF] rats), 13 and patients with heart failure. 12, 16, 51, 52 Only 2 groups have shown no alteration in peak [Ca 2ϩ ] i in ventricular cells from failing human hearts. 5,53 These differences may be attributable, in part, to differences in temperature or stimulation frequency. 52, 54 In addition, cardiac muscle from failing human hearts shows a decrease in active tension at stimulation rates Ͼ50 bpm. 52, 54 Sipido et al 54 showed that this negative force frequency curve is due to a decrease in the amplitude of [Ca 2ϩ ] i at higher pacing rates (Ͼ0.5 Hz). This, in turn, may be due to the inhibition of the L-type Ca 2ϩ current observed in failing human ventricular cells at high pacing rates, which would decrease both the trigger for SR Ca 2ϩ release and the Ca 2ϩ content of the SR. Similar to our data, Bing et al 9 measured a 17% increase in [Ca 2ϩ ] i amplitude in 18-month-old SHRs before the onset of heart failure, although this change did not achieve statistical significance. In addition, Brooksby et al 40 noted a 34% increase in [Ca 2ϩ ] i amplitude in 16-week-old SHRs in response to field stimulation, although no change was observed in voltage-clamp studies with depolarizations of short duration. Therefore, most models of cardiac hypertrophy with an accelerated progression to heart failure show either un- Figure 6 . Immunoblots of ventricular homogenates from 3 control hearts (lanes 1-3) and 3 SHR hearts from 6-month-old rats (4 -6) . RyR indicates ryanodine receptor; SERCA2a, cardiac isoform of SR Ca 2ϩ -ATPase; CSQ, calsequestrin; triadin 1, the predominant triadin isoform in heart, which is partially glycosylated () 35 13 who noted no increase in Ca 2ϩ spark amplitude in either Dahl salt-sensitive rats with hypertrophy or in SH-HF rats. In both of these animal models, the progression of cardiac hypertrophy is rapid, and [Ca 2ϩ ] i amplitude was decreased. The SHRs we studied had mild cardiac hypertrophy with no clinical echocardiographic or histological signs of heart failure.
The increase in the amplitude of the Ca 2ϩ sparks reflects a redistribution of Ca 2ϩ sparks to a population in which the amplitude is larger. Initially, Ca 2ϩ sparks were thought to reflect the "elemental" release of Ca 2ϩ from the SR with a single distribution of amplitudes. 17 The appearance of 2 populations of Ca 2ϩ sparks in this study challenges this concept and is not due to out-of-focus events, as revealed by the absence of a correlation between Ca 2ϩ spark amplitude and kinetics. 30, 37 Multiple populations of Ca 2ϩ sparks have also been identified in rat right-ventricular trabeculae 55 and guinea pig myocytes. 56 The shift in the Ca 2ϩ sparks to a population of larger amplitude coupled with no change in I Ca,L or the density of ryanodine receptors indicates a fundamental alteration in the coupling between the triggering and release of Ca 2ϩ from the SR in hypertrophic cells. Gómez et al 13 reached a similar conclusion, although based on very different results. In their experiments, there was a decrease in the [Ca 2ϩ ] i in Dahl salt-sensitive and SH-HF rats that was not accompanied by changes in the I Ca,L or the Ca 2ϩ sparks. Taken together, these studies indicate that the contractile abnormalities seen in cardiac hypertrophy and its progression to heart failure might be explained, in large part, by alterations in the coupling between Ca 2ϩ entry through the L-type Ca 2ϩ channel and Ca 2ϩ release from the SR. However, the big Ca 2ϩ sparks seen in SHRs with cardiac hypertrophy cannot be understood in terms of an increase in "gain" per se. The relation between the Ca 2ϩ influx and SR Ca 2ϩ release has been defined previously at the macroscopic or whole-cell level as gain and quantified as the ratio of the peak influx of Ca 2ϩ (determined from I Ca,L ) and the peak release of Ca 2ϩ from the SR (calculated from whole-cell [Ca 2ϩ ] i transients). 57 Within the context of the individual or microscopic events of SR Ca 2ϩ release (ie, Ca 2ϩ sparks), gain has been further defined as the ratio of the peak L-type Ca 2ϩ current and the peak number of evoked Ca 2ϩ sparks. 19 Defined in these terms, an increase in gain would be reflected microscopically as an increase in the peak number of evoked Ca 2ϩ sparks of similar amplitude and kinetics and macroscopically as an increase in the amplitude of the whole-cell [Ca 2ϩ ] i transient. In other words, an increase in microscopic gain defined in this way could not account for the big Ca 2ϩ sparks observed in our study. Alternatively, big sparks could be understood in terms of hypertrophy-related alterations in the following ways: (1) Figure 3 ) and there was no demonstrable increase in the expression of Ca 2ϩ -ATPase in SHRs ( Figure 5 ). The dissociation between the decline of [Ca 2ϩ ] i and cell shortening indicates a change either in the Ca 2ϩ affinity of the contractile proteins or in the characteristics of the protein(s) responsible for the restoration of resting cell shape. Several studies have shown no change in the Ca 2ϩ sensitivity of the contractile proteins with the development of hypertrophy and heart failure. 41, 56, 58 Therefore, it appears that the slowed relaxation (diastolic dysfunction) observed with mild cardiac hypertrophy may be better explained by an alteration in structure and/or function of intracellular structural proteins that restore the resting shape of rat ventricular cells after contraction. 59 Overall, our results show that cardiac hypertrophy is associated with an increase in the amount of Ca 2ϩ released from the SR. Since prolonged increases in [Ca 2ϩ ] i stimulate calcineurin, it is interesting to speculate that hypertrophymediated increases in cytosolic Ca 2ϩ may underlie the recently reported calcineurin-dependent transcriptional pathway for cardiac hypertrophy. 60 This speculation is supported by the observations that (1) calcineurin inhibitors, cyclosporin and FK506, prevented cardiac hypertrophy in transgenic mice predisposed to develop cardiac hypertrophy, and (2) cyclosporin prevented the increase in heart/body weight ratios in an abdominal-banded murine model of pressureoverload hypertrophy. 61 
Experimental Model of Hypertensive Heart Disease
In our experiments, we used the SHR as the model for left-ventricular hypertrophy, because it may better mimic the clinical course of untreated or poorly controlled essential hypertension in humans. 2, 62, 63 These animals have a stable and homogeneous expression of systemic hypertension with distinct and easily identifiable phases of cardiac involvement. Initially, the animals develop hypertension without cardiac hypertrophy (Ͻ9 weeks of age). Over time (6 to 12 months of age), the animals gradually develop concentric cardiac hyper-trophy, which eventually progresses to cardiac dilatation, heart failure, and sudden death (18 to 24 months of age). In addition, these animals have alterations in hemodynamics, renal function, peripheral resistance, and sympathetic tone that resemble changes seen in some patients with clinical hypertension.
This model does however, have limitations. The genetic variables that promote hypertension in the SHR model are probably polygenic. Whether the genetic variables are identical or overlap with those in hypertensive patients is unknown. In addition, the action potential in rats is typically shorter in duration that in humans. These differences can be attributed to changes in the outward K ϩ currents rather than to changes in the inward Ca 2ϩ currents. 64 It is also likely that data from SHRs may not be applicable to models in which pressure overload is created by other means. Nevertheless, the SHR model offers an opportunity to study the cellular changes responsible for the contractile abnormalities that occur during development and progression of hypertensive heart disease.
Limitations
In this study, [Ca 2ϩ ] i was determined from Fluo 3 fluorescence using the self-ratio method. 17 ] i was different in the Indo 1 experiments, the change, if any, would be expected to be similar in SHRs and controls, and thus would not alter the conclusions. In fact, resting [Ca 2ϩ ] i would have to increase by at least 60 nmol/L in SHRs to account for the overall increase in the amplitude of Ca 2ϩ sparks that we observed. In addition, the similarities in the amplitudes of the different distributions of Ca 2ϩ sparks in control ( Figure 4A ) and SHR cells ( Figure  4B ) also suggests that there is not a substantial difference in resting [Ca 2ϩ ] i between control and SHR cells.
